Clinical Trial Update: Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates a Phase 2/3 study of eftilagimod alpha in combination with paclitaxel for metastatic breast cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• eftilagimod alpha (eftilagimod alpha)

Snippet

Sponsor: Immutep S.A.S. | Conditions: Breast Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING